Skip to main content

Acutus Medical’s Pulsed Field Ablation System To Be Featured During 27th Annual AF Symposium

Written by Customer Service on . Posted in Public Companies.

CARLSBAD, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the company’s attendance at the 27th Annual AF Symposium.

Cases performed at Na Homolce Hospital in Prague, Czech Republic, by physicians Jacob Koruth, M.D., Mount Sinai Health System, Jan Petru, M.D., Na Homolce Hospital, and Vivek Reddy, M.D., Director, Cardiac Arrhythmia Service, Mount Sinai Health System, will feature the AcQMap 3D Imaging and Mapping System, the AcQBlate Force catheter*, and Acutus’ focal force sensing Pulsed Field Ablation (PFA) system**. Petr Neuzil, M.D., Ph.D., FESC, Na Homolce’s Head of Cardiology and Principal Investigator for the AcQForce PFA-CE study, will present the cases on Saturday, January 15, between 10 a.m. and 12:30 p.m. ET, highlighting the versatility of Acutus technology to map and treat a variety of arrhythmias with a single system.

Additionally, abstract poster presentations demonstrating the efficiency and efficacy of the AcQMap 3D Imaging and Mapping System, as well as the AcQCross Universal Transseptal Crossing System, will be on display. To learn more about Acutus Medical’s complete portfolio of access, diagnostic, mapping and therapy products, please visit https://acutusmedical.com.

The symposium brings together hundreds of leaders in the field of electrophysiology from across the world to educate and present the latest clinical, technological and procedural advancements for the management of atrial fibrillation (AF). To register for the 27th Annual International AF Symposium, an informative three-day scientific program, and for more information on CME, visit https://www.afsymposium.com/.

*AcQBlate Force is currently indicated for RF energy in Europe and is investigational in the U.S.
**The Acutus PFA System is under investigation in CE Mark countries.

About Acutus Medical
Acutus Medical is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Acutus is committed to advancing the field of electrophysiology with a unique array of products and technologies which will enable more physicians to treat more patients more efficiently and effectively. Through internal product development, acquisitions and global partnerships, Acutus has established a global sales presence delivering a broad portfolio of highly differentiated electrophysiology products that provide its customers with a complete solution for catheter-based treatment of cardiac arrhythmias. Founded in 2011, Acutus is based in Carlsbad, California.

Follow Acutus Medical on: Twitter, LinkedIn, YouTube and Facebook.

US Media Contacts
Holly Windler
(619) 929-1275
holly.windler@acutus.com

Adam King
(260) 408-5383
acutus@levitatenow.com

Investor Contact
Caroline Corner
(415) 202-5678
caroline.corner@westwicke.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.